Targeting colon cancer with the novel STAT3 inhibitor bruceantinol View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-10-22

AUTHORS

Ning Wei, Jun Li, Cheng Fang, Jin Chang, Vasiliki Xirou, Nick K. Syrigos, Benjamin J. Marks, Edward Chu, John C. Schmitz

ABSTRACT

STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in ~70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure–activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was observed in a STAT3−/− tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC. More... »

PAGES

1676-1687

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41388-018-0547-y

DOI

http://dx.doi.org/10.1038/s41388-018-0547-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107761860

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30348989


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colonic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HCT116 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Docking Simulation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Binding", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quassins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "STAT3 Transcription Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Structure-Activity Relationship", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Ning", 
        "id": "sg:person.01342751116.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342751116.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Basic Medical Science College, Liaoning University of Traditional Chinese Medicine, Shenyang, China", 
          "id": "http://www.grid.ac/institutes/grid.411464.2", 
          "name": [
            "Basic Medical Science College, Liaoning University of Traditional Chinese Medicine, Shenyang, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Jun", 
        "id": "sg:person.012530365377.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012530365377.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Computational Modeling & Simulation Program, University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Computational Modeling & Simulation Program, University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fang", 
        "givenName": "Cheng", 
        "id": "sg:person.01103155221.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103155221.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Taishan Medical University, Taian City, China", 
          "id": "http://www.grid.ac/institutes/grid.410638.8", 
          "name": [
            "Department of Oncology, Taishan Medical University, Taian City, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chang", 
        "givenName": "Jin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Athens Medical School, Athens, Greece", 
          "id": "http://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "University of Athens Medical School, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xirou", 
        "givenName": "Vasiliki", 
        "id": "sg:person.01336734043.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336734043.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Athens Medical School, Athens, Greece", 
          "id": "http://www.grid.ac/institutes/grid.5216.0", 
          "name": [
            "University of Athens Medical School, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Syrigos", 
        "givenName": "Nick K.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marks", 
        "givenName": "Benjamin J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chu", 
        "givenName": "Edward", 
        "id": "sg:person.01003652000.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA", 
          "id": "http://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA", 
            "Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schmitz", 
        "givenName": "John C.", 
        "id": "sg:person.01103077575.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103077575.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/onc.2015.215", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008190247", 
          "https://doi.org/10.1038/onc.2015.215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00208896", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001870372", 
          "https://doi.org/10.1007/bf00208896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2013.16", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024067558", 
          "https://doi.org/10.1038/onc.2013.16"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2013.131", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001858712", 
          "https://doi.org/10.1038/onc.2013.131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11655-016-2501-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011178831", 
          "https://doi.org/10.1007/s11655-016-2501-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2402696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038282588", 
          "https://doi.org/10.1038/sj.leu.2402696"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-22", 
    "datePublishedReg": "2018-10-22", 
    "description": "STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in ~70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50\u2009=\u20092.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure\u2013activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4\u2009mg/kg BOL significantly inhibited CRC tumor xenografts [p\u2009<\u20090.001], but no effect was observed in a STAT3\u2212/\u2212 tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41388-018-0547-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6999262", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438856", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1097543", 
        "issn": [
          "0950-9232", 
          "1476-5594"
        ], 
        "name": "Oncogene", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "38"
      }
    ], 
    "keywords": [
      "STAT3 inhibitor", 
      "human colorectal cancer model", 
      "MEK inhibitors", 
      "colorectal cancer model", 
      "human cancers", 
      "novel STAT3 inhibitor", 
      "IL-6-induced STAT3 activation", 
      "potent antitumor activity", 
      "time-dependent manner", 
      "anti-apoptosis factors", 
      "human CRC", 
      "tumor xenografts", 
      "colon cancer", 
      "cancer model", 
      "Mcl-1 induction", 
      "tumor model", 
      "MEK inhibition", 
      "therapeutic STAT3 inhibitor", 
      "STAT3 target genes", 
      "antitumor activity", 
      "Additional studies", 
      "cancer", 
      "cell cycle regulators", 
      "STAT3 activation", 
      "oncogenic signaling", 
      "structure-activity relationship studies", 
      "inhibitors", 
      "STAT3", 
      "resistance mechanisms", 
      "transcriptional mediators", 
      "treatment", 
      "target genes", 
      "relationship studies", 
      "xenografts", 
      "dose", 
      "bruceantinol", 
      "administration", 
      "CRC", 
      "mediators", 
      "DNA-binding ability", 
      "inhibition", 
      "study", 
      "induction", 
      "activation", 
      "signaling", 
      "findings", 
      "ability", 
      "factors", 
      "activity", 
      "genes", 
      "regulator", 
      "effect", 
      "transcription", 
      "manner", 
      "mechanism", 
      "combination", 
      "development", 
      "Herein", 
      "C15 side chain", 
      "area", 
      "model", 
      "repression", 
      "research", 
      "side chains", 
      "active area", 
      "chain", 
      "vivo human colorectal cancer (CRC) models", 
      "STAT3 DNA-binding ability", 
      "CRC tumor xenografts", 
      "novel therapeutic STAT3 inhibitor", 
      "novel STAT3 inhibitor bruceantinol", 
      "STAT3 inhibitor bruceantinol", 
      "inhibitor bruceantinol"
    ], 
    "name": "Targeting colon cancer with the novel STAT3 inhibitor bruceantinol", 
    "pagination": "1676-1687", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107761860"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41388-018-0547-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30348989"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41388-018-0547-y", 
      "https://app.dimensions.ai/details/publication/pub.1107761860"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_793.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41388-018-0547-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41388-018-0547-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41388-018-0547-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41388-018-0547-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41388-018-0547-y'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      22 PREDICATES      124 URIs      110 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41388-018-0547-y schema:about N08a14d31213d49ff906fc63c5e2710bf
2 N0a4202f8d3b045bf919474344b5cf2eb
3 N10ce8d08b03448a784f48055d38f9fa2
4 N1fcce4262b434f2681456447cb290f7e
5 N28d67be64577485ab0e2cf0bf64e771f
6 N3afa699ecf9c4c60943ecab9c3bf0de1
7 N3f4787c84f294516992094af7078f62e
8 N435e13b733b6488598b36614fb7641fd
9 N674386725db14293a257ab6d69df3e7b
10 N6b2a4603382a48698118d131da8f54c9
11 N7fd7eb6615084e5793b2990da9e6fd2f
12 N839349cc9c5e4924bd1ee299403bc18c
13 N879ae6e130534b1092017eea5696e3f8
14 N927d26468162452fac550e5da063f8f0
15 N9dbc748409af4475be8cb1f0c8f98a61
16 Nbcb188f05e4e4fe88e6e7d0dfd0f2d4a
17 Nbcf07b5d6a0e406f8e5903f9e40dd8e5
18 Nd0e72aba73a244d58da6343f9b9aefcc
19 Ne9d96ac5e9c94764a5c6bfd5a3d3a912
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N90b3db34c1cc468fb18dfe812527c05a
23 schema:citation sg:pub.10.1007/bf00208896
24 sg:pub.10.1007/s11655-016-2501-6
25 sg:pub.10.1038/onc.2013.131
26 sg:pub.10.1038/onc.2013.16
27 sg:pub.10.1038/onc.2015.215
28 sg:pub.10.1038/sj.leu.2402696
29 schema:datePublished 2018-10-22
30 schema:datePublishedReg 2018-10-22
31 schema:description STAT3, a transcriptional mediator of oncogenic signaling, is constitutively active in ~70% of human cancers. The development of STAT3 inhibitors remains an active area of research as no inhibitors have yet to be approved for the treatment of human cancer. Herein, we revealed that bruceantinol (BOL) is a novel STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. BOL strongly inhibited STAT3 DNA-binding ability (IC50 = 2.4 pM), blocked the constitutive and IL-6-induced STAT3 activation in a dose- and time-dependent manner, and suppressed transcription of STAT3 target genes encoding anti-apoptosis factors (MCL-1, PTTG1, and survivin) and cell-cycle regulators (c-Myc). Structure–activity relationship studies demonstrated that the C15 side chain on BOL affected its ability to bind STAT3. Administration of 4 mg/kg BOL significantly inhibited CRC tumor xenografts [p < 0.001], but no effect was observed in a STAT3−/− tumor model. Additional studies showed that BOL effectively sensitized MEK inhibitors through repression of p-STAT3 and MCL-1 induction, known resistance mechanisms of MEK inhibition. Taken together, our findings suggest BOL is a novel therapeutic STAT3 inhibitor that can be used either alone or in combination with MEK inhibitors for the treatment of human CRC.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N8ddbd42067ca42fca1d2a2d68f58de43
36 Nbe27321585474885920756bc35a81b9d
37 sg:journal.1097543
38 schema:keywords Additional studies
39 C15 side chain
40 CRC
41 CRC tumor xenografts
42 DNA-binding ability
43 Herein
44 IL-6-induced STAT3 activation
45 MEK inhibition
46 MEK inhibitors
47 Mcl-1 induction
48 STAT3
49 STAT3 DNA-binding ability
50 STAT3 activation
51 STAT3 inhibitor
52 STAT3 inhibitor bruceantinol
53 STAT3 target genes
54 ability
55 activation
56 active area
57 activity
58 administration
59 anti-apoptosis factors
60 antitumor activity
61 area
62 bruceantinol
63 cancer
64 cancer model
65 cell cycle regulators
66 chain
67 colon cancer
68 colorectal cancer model
69 combination
70 development
71 dose
72 effect
73 factors
74 findings
75 genes
76 human CRC
77 human cancers
78 human colorectal cancer model
79 induction
80 inhibition
81 inhibitor bruceantinol
82 inhibitors
83 manner
84 mechanism
85 mediators
86 model
87 novel STAT3 inhibitor
88 novel STAT3 inhibitor bruceantinol
89 novel therapeutic STAT3 inhibitor
90 oncogenic signaling
91 potent antitumor activity
92 regulator
93 relationship studies
94 repression
95 research
96 resistance mechanisms
97 side chains
98 signaling
99 structure-activity relationship studies
100 study
101 target genes
102 therapeutic STAT3 inhibitor
103 time-dependent manner
104 transcription
105 transcriptional mediators
106 treatment
107 tumor model
108 tumor xenografts
109 vivo human colorectal cancer (CRC) models
110 xenografts
111 schema:name Targeting colon cancer with the novel STAT3 inhibitor bruceantinol
112 schema:pagination 1676-1687
113 schema:productId N36f5841812e442a2928dcaec928386ce
114 Naa0ceedc9f05469c997eef4b12cb9d12
115 Nc4d6ae3819ed4e6d929449818b9b272c
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107761860
117 https://doi.org/10.1038/s41388-018-0547-y
118 schema:sdDatePublished 2022-01-01T18:47
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N011db10ada774454a1fc00878a9762fc
121 schema:url https://doi.org/10.1038/s41388-018-0547-y
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N011db10ada774454a1fc00878a9762fc schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N08a14d31213d49ff906fc63c5e2710bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Female
129 rdf:type schema:DefinedTerm
130 N0a4202f8d3b045bf919474344b5cf2eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Gene Expression Regulation
132 rdf:type schema:DefinedTerm
133 N10ce8d08b03448a784f48055d38f9fa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Mice
135 rdf:type schema:DefinedTerm
136 N111e64669b18443b9962c9a863e2cbd7 rdf:first N9b8bceffbf85449883e1e65926ef2651
137 rdf:rest Ne922726f5d9849f3878d269ac955d159
138 N1fcce4262b434f2681456447cb290f7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cell Proliferation
140 rdf:type schema:DefinedTerm
141 N26a9e01382724c14bcbc67cac7501e0a schema:affiliation grid-institutes:grid.410638.8
142 schema:familyName Chang
143 schema:givenName Jin
144 rdf:type schema:Person
145 N28d67be64577485ab0e2cf0bf64e771f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Molecular Docking Simulation
147 rdf:type schema:DefinedTerm
148 N36f5841812e442a2928dcaec928386ce schema:name doi
149 schema:value 10.1038/s41388-018-0547-y
150 rdf:type schema:PropertyValue
151 N3afa699ecf9c4c60943ecab9c3bf0de1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Antineoplastic Agents
153 rdf:type schema:DefinedTerm
154 N3d0a01c3382144d8aea68e1fe52eb52e rdf:first sg:person.01103155221.46
155 rdf:rest Nbcc827a2616f487f94b767e7e76e17b3
156 N3f4787c84f294516992094af7078f62e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name STAT3 Transcription Factor
158 rdf:type schema:DefinedTerm
159 N435e13b733b6488598b36614fb7641fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Time Factors
161 rdf:type schema:DefinedTerm
162 N674386725db14293a257ab6d69df3e7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Quassins
164 rdf:type schema:DefinedTerm
165 N6b2a4603382a48698118d131da8f54c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Cell Line, Tumor
167 rdf:type schema:DefinedTerm
168 N7bac2bc43c1a4998993dbf83cb6bcbd2 rdf:first sg:person.01103077575.12
169 rdf:rest rdf:nil
170 N7fd7eb6615084e5793b2990da9e6fd2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Dose-Response Relationship, Drug
172 rdf:type schema:DefinedTerm
173 N839349cc9c5e4924bd1ee299403bc18c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Structure-Activity Relationship
175 rdf:type schema:DefinedTerm
176 N879ae6e130534b1092017eea5696e3f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Xenograft Model Antitumor Assays
178 rdf:type schema:DefinedTerm
179 N89f8f05d65544834a368c44f5da67ac5 rdf:first sg:person.012530365377.45
180 rdf:rest N3d0a01c3382144d8aea68e1fe52eb52e
181 N8ddbd42067ca42fca1d2a2d68f58de43 schema:issueNumber 10
182 rdf:type schema:PublicationIssue
183 N90b3db34c1cc468fb18dfe812527c05a rdf:first sg:person.01342751116.39
184 rdf:rest N89f8f05d65544834a368c44f5da67ac5
185 N927d26468162452fac550e5da063f8f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 N9b8bceffbf85449883e1e65926ef2651 schema:affiliation grid-institutes:grid.5216.0
189 schema:familyName Syrigos
190 schema:givenName Nick K.
191 rdf:type schema:Person
192 N9dbc748409af4475be8cb1f0c8f98a61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Protein Binding
194 rdf:type schema:DefinedTerm
195 Naa0ceedc9f05469c997eef4b12cb9d12 schema:name dimensions_id
196 schema:value pub.1107761860
197 rdf:type schema:PropertyValue
198 Nb0eca91e37b44497b1c832216f9c7c29 schema:affiliation grid-institutes:grid.21925.3d
199 schema:familyName Marks
200 schema:givenName Benjamin J.
201 rdf:type schema:Person
202 Nbcb188f05e4e4fe88e6e7d0dfd0f2d4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Cell Survival
204 rdf:type schema:DefinedTerm
205 Nbcc827a2616f487f94b767e7e76e17b3 rdf:first N26a9e01382724c14bcbc67cac7501e0a
206 rdf:rest Nf7411c58d478459dae6b9cfce9057608
207 Nbcf07b5d6a0e406f8e5903f9e40dd8e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Animals
209 rdf:type schema:DefinedTerm
210 Nbe27321585474885920756bc35a81b9d schema:volumeNumber 38
211 rdf:type schema:PublicationVolume
212 Nc4d6ae3819ed4e6d929449818b9b272c schema:name pubmed_id
213 schema:value 30348989
214 rdf:type schema:PropertyValue
215 Nd0e72aba73a244d58da6343f9b9aefcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name HCT116 Cells
217 rdf:type schema:DefinedTerm
218 Ndb25b0d64e7d4eb188db961dac416285 rdf:first sg:person.01003652000.28
219 rdf:rest N7bac2bc43c1a4998993dbf83cb6bcbd2
220 Ne922726f5d9849f3878d269ac955d159 rdf:first Nb0eca91e37b44497b1c832216f9c7c29
221 rdf:rest Ndb25b0d64e7d4eb188db961dac416285
222 Ne9d96ac5e9c94764a5c6bfd5a3d3a912 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Colonic Neoplasms
224 rdf:type schema:DefinedTerm
225 Nf7411c58d478459dae6b9cfce9057608 rdf:first sg:person.01336734043.93
226 rdf:rest N111e64669b18443b9962c9a863e2cbd7
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
231 schema:name Oncology and Carcinogenesis
232 rdf:type schema:DefinedTerm
233 sg:grant.2438856 http://pending.schema.org/fundedItem sg:pub.10.1038/s41388-018-0547-y
234 rdf:type schema:MonetaryGrant
235 sg:grant.6999262 http://pending.schema.org/fundedItem sg:pub.10.1038/s41388-018-0547-y
236 rdf:type schema:MonetaryGrant
237 sg:journal.1097543 schema:issn 0950-9232
238 1476-5594
239 schema:name Oncogene
240 schema:publisher Springer Nature
241 rdf:type schema:Periodical
242 sg:person.01003652000.28 schema:affiliation grid-institutes:grid.21925.3d
243 schema:familyName Chu
244 schema:givenName Edward
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003652000.28
246 rdf:type schema:Person
247 sg:person.01103077575.12 schema:affiliation grid-institutes:grid.21925.3d
248 schema:familyName Schmitz
249 schema:givenName John C.
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103077575.12
251 rdf:type schema:Person
252 sg:person.01103155221.46 schema:affiliation grid-institutes:grid.21925.3d
253 schema:familyName Fang
254 schema:givenName Cheng
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103155221.46
256 rdf:type schema:Person
257 sg:person.012530365377.45 schema:affiliation grid-institutes:grid.411464.2
258 schema:familyName Li
259 schema:givenName Jun
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012530365377.45
261 rdf:type schema:Person
262 sg:person.01336734043.93 schema:affiliation grid-institutes:grid.5216.0
263 schema:familyName Xirou
264 schema:givenName Vasiliki
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336734043.93
266 rdf:type schema:Person
267 sg:person.01342751116.39 schema:affiliation grid-institutes:grid.21925.3d
268 schema:familyName Wei
269 schema:givenName Ning
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342751116.39
271 rdf:type schema:Person
272 sg:pub.10.1007/bf00208896 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001870372
273 https://doi.org/10.1007/bf00208896
274 rdf:type schema:CreativeWork
275 sg:pub.10.1007/s11655-016-2501-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011178831
276 https://doi.org/10.1007/s11655-016-2501-6
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/onc.2013.131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001858712
279 https://doi.org/10.1038/onc.2013.131
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/onc.2013.16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024067558
282 https://doi.org/10.1038/onc.2013.16
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/onc.2015.215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008190247
285 https://doi.org/10.1038/onc.2015.215
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/sj.leu.2402696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038282588
288 https://doi.org/10.1038/sj.leu.2402696
289 rdf:type schema:CreativeWork
290 grid-institutes:grid.21925.3d schema:alternateName Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
291 Computational Modeling & Simulation Program, University of Pittsburgh, Pittsburgh, PA, USA
292 schema:name Cancer Therapeutics Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
293 Computational Modeling & Simulation Program, University of Pittsburgh, Pittsburgh, PA, USA
294 Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
295 rdf:type schema:Organization
296 grid-institutes:grid.410638.8 schema:alternateName Department of Oncology, Taishan Medical University, Taian City, China
297 schema:name Department of Oncology, Taishan Medical University, Taian City, China
298 rdf:type schema:Organization
299 grid-institutes:grid.411464.2 schema:alternateName Basic Medical Science College, Liaoning University of Traditional Chinese Medicine, Shenyang, China
300 schema:name Basic Medical Science College, Liaoning University of Traditional Chinese Medicine, Shenyang, China
301 rdf:type schema:Organization
302 grid-institutes:grid.5216.0 schema:alternateName University of Athens Medical School, Athens, Greece
303 schema:name University of Athens Medical School, Athens, Greece
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...